

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCI United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/551,990	10/551,990 03/06/2006		Kazutomo Inoue	2005_1502A	6411	
513	7590	08/23/2006		EXAM	EXAMINER	
	•	D & PONACK, I	GOUGH, TIFFA	GOUGH, TIFFANY MAUREEN		
2033 K STREET N. W. SUITE 800				ART UNIT	PAPER NUMBER	
WASHINGT	ON, DC	20006-1021	1651			

DATE MAILED: 08/23/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(a)
		Application No.	Applicant(s)
Office Action Summary		10/551,990	INOUE ET AL.
		Examiner	Art Unit
		Tiffany M. Gough	1651
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Operiod for reply is specified above, the maximum statutory period we are to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timustilly apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. they filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		·	
2a)	Responsive to communication(s) filed on This action is <b>FINAL</b> . 2b) This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro	
		x parte Quayre, 1955 O.D. 11, 45	0.0.210.
5) 6) 7)	Claim(s) 1-11 is/are pending in the application of Claim(s) 1-11 is/are pending in the application day Of the above claim(s) is/are withdraw Claim(s) is/are allowed.  Claim(s) is/are rejected.  Claim(s) is/are objected to.  Claim(s) 1-11 are subject to restriction and/or	vn from consideration.	•
Applicat	ion Papers		
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Example 1.	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority (	under 35 U.S.C. § 119		
а)	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the priority application from the International Bureau  See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
2) Notice 3) Infor	ot(s)  Dee of References Cited (PTO-892)  Dee of Draftsperson's Patent Drawing Review (PTO-948)  The mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  The No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	

Art Unit: 1651

## **DETAILED ACTION**

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-9,17, drawn to a cellular preparation.

Group II, claim(s) 10,11,15, drawn to a method of prevention and treating endocrine or metabolic disease.

Group III, claim(s) 12, drawn to a method of prevention and treating hemophilia.

Group IV, claim(s) 13, drawn to a method of prevention and treating bone disease.

Group V. claim(s) 14, drawn to a method of prevention and treating cancer.

Group VI, claim(s) 16, drawn to a method of preparing a cellular preparation.

The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: A "special technical feature" is defined by PCT Rule 13.2 as "those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art." In the instant case, as discussed below, a number of the claimed

Art Unit: 1651

inventions fail to make any contribution over the prior art. Because a number of the claimed inventions fail to make any contribution over the prior art, the claims as filed fail to contain a single common special technical feature supporting a showing unity of invention.

Specifically, US 5,759,830 demonstrates that the inventions described in claims 1-11 lack novelty and inventive step. Because those claims fail to make a contribution over the prior art, it is clear that all claims as filed fail to provide special technical feature common to all claimed inventions. Because the claims as filed lack a common special technical feature, the claims lack unity.

Lack of a common special technical feature, and therefore lack of unity, is further demonstrated by the fact that the various methods of treating an array of diseases and conditions having vastly different properties. Moreover, because the various processes recited in the claims recite treating different diseases, it is clear that the process claim also lack a single common special technical feature, and therefore also lack unity.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

a). cells in claims 4

Applicant is required, in reply to this action, to elect a single species from (a) to which the claims shall be restricted if no generic claim is finally held to be allowable.

Art Unit: 1651

The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

Group I corresponds to claims 1-9,17 Group II corresponds to claims 10,11,15 Group IV corresponds to claims 12 Group V corresponds to claims 13 Group V corresponds to claims 14 Group VI corresponds to claims 16

he following claim(s) are generic: 1

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Art Unit: 1651

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tiffany M. Gough whose telephone number is 571-272-0697. The examiner can normally be reached on M-F 8-5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/551,990 Page 6

Art Unit: 1651

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

tmg

RUTH DAVIS
PRIMARY EXAMINER